GLOW

BPC-157: TB-500: GHK-Cu: Combined activity

• Angiogenesis and microvascular support signaling
• Fibroblast activity and tissue repair signaling
• Nitric oxide related signaling and inflammation balance endpoints
• Actin regulation and cell migration signaling
• Tissue remodeling and repair related pathways
• Vascular development signals in injury based models
• Collagen synthesis and extracellular matrix support
• Gene expression modulation tied to repair and inflammation control
• Antioxidant and oxidative stress resilience signaling
• Skin quality and tissue remodeling endpoints
• Enhanced tissue remodeling and repair coordination
• Stronger collagen and extracellular matrix support
• Increased cellular migration and recovery signaling
• Reduced inflammation markers in select injury models
• Skin appearance and elasticity related endpoints in cosmetic models

• Improved skin texture and firmness signals
• Enhanced wound healing related endpoints
• Increased fibroblast activity and collagen alignment markers
• Reduced wrinkle related signals in cosmetic tissue models
• Reduced inflammation markers in select paradigms
• Improved oxidative stress resilience and cellular protection endpoints
• Faster recovery signals in injury based or high stress models

Potential observations discussed in research contexts may include: Overall, the components are often described as having low adverse event frequency in preclinical settings, but tolerability remains dose dependent and model dependent.

• Temporary redness at the application or administration site depending on model conditions
• Mild fatigue
• Transient headache
• Rare copper related skin darkening signals attributed to the GHK-Cu component in some contexts